vs

ALTISOURCE PORTFOLIO SOLUTIONS S.A.(ASPS)与Health Catalyst, Inc.(HCAT)财务数据对比。点击上方公司名可切换其他公司

Health Catalyst, Inc.的季度营收约是ALTISOURCE PORTFOLIO SOLUTIONS S.A.的1.8倍($74.7M vs $42.3M),ALTISOURCE PORTFOLIO SOLUTIONS S.A.净利率更高(-16.8% vs -121.9%,领先105.0%),ALTISOURCE PORTFOLIO SOLUTIONS S.A.同比增速更快(3.2% vs -6.2%),Health Catalyst, Inc.自由现金流更多($9.6M vs $-525.0K),过去两年ALTISOURCE PORTFOLIO SOLUTIONS S.A.的营收复合增速更高(3.6% vs -0.0%)

Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商,为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案,优化资产管理、房产交易等业务流程,提升客户运营效率。

Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业,专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse,原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征(LEMS)的治疗,2018年11月又获批可用于6岁及以上儿童LEMS患者。

ASPS vs HCAT — 直观对比

营收规模更大
HCAT
HCAT
是对方的1.8倍
HCAT
$74.7M
$42.3M
ASPS
营收增速更快
ASPS
ASPS
高出9.4%
ASPS
3.2%
-6.2%
HCAT
净利率更高
ASPS
ASPS
高出105.0%
ASPS
-16.8%
-121.9%
HCAT
自由现金流更多
HCAT
HCAT
多$10.2M
HCAT
$9.6M
$-525.0K
ASPS
两年增速更快
ASPS
ASPS
近两年复合增速
ASPS
3.6%
-0.0%
HCAT

损益表 — Q4 FY2025 vs Q4 FY2025

指标
ASPS
ASPS
HCAT
HCAT
营收
$42.3M
$74.7M
净利润
$-7.1M
$-91.0M
毛利率
26.5%
营业利润率
-15.5%
-115.3%
净利率
-16.8%
-121.9%
营收同比
3.2%
-6.2%
净利润同比
18.2%
-340.3%
每股收益(稀释后)
$-1.02
$-1.29

绿色 = 该指标领先。财年不对齐时期间可能不同

8季度营收与利润趋势

并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配

营收
ASPS
ASPS
HCAT
HCAT
Q4 25
$42.3M
$74.7M
Q3 25
$41.9M
$76.3M
Q2 25
$43.3M
$80.7M
Q1 25
$43.4M
$79.4M
Q4 24
$41.0M
$79.6M
Q3 24
$40.5M
$76.4M
Q2 24
$39.1M
$75.9M
Q1 24
$39.5M
$74.7M
净利润
ASPS
ASPS
HCAT
HCAT
Q4 25
$-7.1M
$-91.0M
Q3 25
$-2.3M
$-22.2M
Q2 25
$16.7M
$-41.0M
Q1 25
$-5.3M
$-23.7M
Q4 24
$-8.7M
$-20.7M
Q3 24
$-9.3M
$-14.7M
Q2 24
$-8.3M
$-13.5M
Q1 24
$-9.2M
$-20.6M
毛利率
ASPS
ASPS
HCAT
HCAT
Q4 25
26.5%
Q3 25
27.1%
52.6%
Q2 25
30.1%
Q1 25
30.7%
Q4 24
30.3%
Q3 24
29.8%
47.5%
Q2 24
32.5%
Q1 24
31.2%
营业利润率
ASPS
ASPS
HCAT
HCAT
Q4 25
-15.5%
-115.3%
Q3 25
1.2%
-22.9%
Q2 25
7.5%
-46.0%
Q1 25
7.5%
-25.4%
Q4 24
1.4%
-22.0%
Q3 24
2.7%
-17.9%
Q2 24
5.3%
-20.8%
Q1 24
-1.4%
-30.5%
净利率
ASPS
ASPS
HCAT
HCAT
Q4 25
-16.8%
-121.9%
Q3 25
-5.5%
-29.1%
Q2 25
38.5%
-50.8%
Q1 25
-12.1%
-29.9%
Q4 24
-21.3%
-26.0%
Q3 24
-23.0%
-19.3%
Q2 24
-21.1%
-17.8%
Q1 24
-23.2%
-27.6%
每股收益(稀释后)
ASPS
ASPS
HCAT
HCAT
Q4 25
$-1.02
$-1.29
Q3 25
$-0.22
$-0.32
Q2 25
$1.48
$-0.59
Q1 25
$-0.09
$-0.35
Q4 24
$-4.72
$-0.33
Q3 24
$-2.61
$-0.24
Q2 24
$-2.33
$-0.23
Q1 24
$-0.33
$-0.35

资产负债表与财务实力

最新季度各公司的流动性、杠杆与账面价值一览

指标
ASPS
ASPS
HCAT
HCAT
现金及短期投资手头流动性
$26.6M
$95.7M
总债务越低越好
$191.1M
$153.3M
股东权益账面价值
$-110.2M
$245.8M
总资产
$139.8M
$502.6M
负债/权益比越低杠杆越低
0.62×

8季度趋势,按日历期对齐

现金及短期投资
ASPS
ASPS
HCAT
HCAT
Q4 25
$26.6M
$95.7M
Q3 25
$28.6M
$91.5M
Q2 25
$30.0M
$97.3M
Q1 25
$30.8M
$342.0M
Q4 24
$29.8M
$392.0M
Q3 24
$28.3M
$387.3M
Q2 24
$29.7M
$308.3M
Q1 24
$29.6M
$327.8M
总债务
ASPS
ASPS
HCAT
HCAT
Q4 25
$191.1M
$153.3M
Q3 25
$192.5M
$153.1M
Q2 25
$193.9M
$153.0M
Q1 25
$195.0M
$382.9M
Q4 24
$230.5M
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
股东权益
ASPS
ASPS
HCAT
HCAT
Q4 25
$-110.2M
$245.8M
Q3 25
$-104.2M
$331.9M
Q2 25
$-102.7M
$347.5M
Q1 25
$-119.8M
$376.8M
Q4 24
$-157.4M
$365.2M
Q3 24
$-149.4M
$355.0M
Q2 24
$-140.8M
$357.0M
Q1 24
$-133.3M
$357.2M
总资产
ASPS
ASPS
HCAT
HCAT
Q4 25
$139.8M
$502.6M
Q3 25
$139.9M
$587.1M
Q2 25
$142.9M
$616.2M
Q1 25
$145.7M
$891.5M
Q4 24
$143.6M
$858.9M
Q3 24
$144.5M
$813.0M
Q2 24
$146.6M
$691.7M
Q1 24
$148.9M
$695.1M
负债/权益比
ASPS
ASPS
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

现金流与资本效率

扣除再投资后实际产生的现金。现金流比净利润更难造假

指标
ASPS
ASPS
HCAT
HCAT
经营现金流最新季度
$-505.0K
$9.9M
自由现金流经营现金流 - 资本支出
$-525.0K
$9.6M
自由现金流率自由现金流/营收
-1.2%
12.9%
资本支出强度资本支出/营收
0.0%
0.4%
现金转化率经营现金流/净利润
过去12个月自由现金流最近4个季度
$-5.1M
$-697.0K

8季度趋势,按日历期对齐

经营现金流
ASPS
ASPS
HCAT
HCAT
Q4 25
$-505.0K
$9.9M
Q3 25
$718.0K
$-464.0K
Q2 25
$-306.0K
$-9.0M
Q1 25
$-5.0M
$280.0K
Q4 24
$-1.4M
$-3.5M
Q3 24
$-1.6M
$6.2M
Q2 24
$180.0K
$1.6M
Q1 24
$-2.2M
$10.3M
自由现金流
ASPS
ASPS
HCAT
HCAT
Q4 25
$-525.0K
$9.6M
Q3 25
$697.0K
$-719.0K
Q2 25
$-309.0K
$-9.2M
Q1 25
$-5.0M
$-390.0K
Q4 24
$-1.4M
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
自由现金流率
ASPS
ASPS
HCAT
HCAT
Q4 25
-1.2%
12.9%
Q3 25
1.7%
-0.9%
Q2 25
-0.7%
-11.4%
Q1 25
-11.5%
-0.5%
Q4 24
-3.4%
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
资本支出强度
ASPS
ASPS
HCAT
HCAT
Q4 25
0.0%
0.4%
Q3 25
0.1%
0.3%
Q2 25
0.0%
0.3%
Q1 25
0.1%
0.8%
Q4 24
0.0%
0.5%
Q3 24
0.0%
0.9%
Q2 24
0.0%
0.4%
Q1 24
0.0%
0.3%
现金转化率
ASPS
ASPS
HCAT
HCAT
Q4 25
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

财务流量对比

营收 → 毛利润 → 营业利润 → 净利润流向图

业务分部营收拆解

ASPS
ASPS

Services$39.9M94%
Revenue Relatedto Technology Platformsand Professional Services$2.4M6%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

相关对比